Healthtech startup Risa Labs has secured $3.5 million in seed funding, with Flipkart co-founder Binny Bansal leading the round.
Other investors include Oncology Ventures, General Catalyst, z21 Ventures, Odd Bird VC, and angel investor Ashish Gupta.
With the fresh funds, Risa plans to expand its technology to 100 cancer centers across the U.S. over the next two years.
The company also aims to build a unified AI-driven layer that connects providers, life sciences companies, and other stakeholders throughout the drug development and treatment lifecycle.
Founded in 2024 by IIT Kanpur alumni Kshitij Jaggi and Kumar Shivang, Risa Labs is on a mission to streamline cancer care through its AI-powered workflow automation platform, BOSS (Business Operating System as a Service).
The platform uses a network of AI agents—including large language models and digital twins—to break down complex administrative processes into smaller, manageable tasks.
Risa Labs is tackling a major challenge in cancer treatment: delays caused by manual and error-prone workflows.
Also Read: Planck Raises Pre-Seed Funding at $500K Valuation
In the U.S., 70% of cancer patients face treatment delays due to prior authorisation issues, with some waiting up to a month—delays that can significantly impact survival rates. BOSS aims to eliminate these bottlenecks.
Already deployed at a U.S. cancer center, BOSS has reduced prior authorisation time from 30 minutes to under five, processed over $1 million in medications, and cut administrative costs by two-thirds.
“Software that was supposed to get work done has become work itself,” said CEO Kshitij Jaggi. “BOSS is designed for a post-ChatGPT world—where expressing intent is all it takes to get the job done.”
Investor Binny Bansal added, “As AI agents unbundle the $4.6 trillion services industry, Risa’s BOSS leads the way—proven in oncology and built to scale.”
